CH1110760852
CH1110760852
POLYPEPTIDE N
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 391.871.000 | 338.695.000 | 15.7% |
| Cost of Revenue | 325.336.000 | 299.422.000 | 8.7% |
| Gross Profit | 66.535.000 | 39.273.000 | 69.4% |
| 57.845.000 | 45.268.000 | 27.8% | |
| Operating Income | 8.690.000 | -5.995.000 | 245.0% |
| Pretax Income | -20.057.000 | -18.145.000 | 10.5% |
| Net Income Common Stockholders | -21.169.000 | -19.564.000 | 8.2% |
| -- | -- | -- | |
| -- | -- | -- |